天目药业：9月1日召开董事会会议

Group 1 - The core viewpoint of the article is that Tianmu Pharmaceutical (SH 600671) held its 15th meeting of the 12th board of directors on September 1, 2025, to discuss the appointment of a new financial director and other documents [1] - For the fiscal year 2024, the revenue composition of Tianmu Pharmaceutical is as follows: health products account for 31.37%, pharmaceutical circulation products account for 21.97%, service-related products account for 19.74%, raw materials account for 12.64%, and traditional Chinese medicine accounts for 11.84% [1] - As of the time of reporting, the market capitalization of Tianmu Pharmaceutical is 2.3 billion yuan [1]